Background: As the number of patients using dermal filler for face augmentation increases, the number of adverse events associated with injection may increase. Unpredictable repositioning of blood vessels and a more tenuous blood supply in the operated nose may increase the risk of ischemia, necrosis, and vascular embolism following the filler injection. Objectives: To highlight the importance of the patient's history of previous cosmetic procedures including rhinoplasty in the emergence of vascular complications. Methods: Our medical records over a two-year period were reviewed retrospectively to identify all patients who were treated at our center for vascular complications associated with facial hyaluronic acid filler injections. In each case, the subject's demographic data (gender and age), habitual status, past medical and surgical history, the symptoms and clinical presentation at the first visit, the time interval between the injection and the onset of symptoms, injected filler material and brand, injection sites, the introduced treatment, and photographs were reviewed carefully. Results: A total of seven patients were identified, each developing skin necrosis following injection of the hyaluronic acid filler. All patients reported a cosmetic rhinoplasty more than three years ago. Conclusions: Our finding confirms the conjecture previously made in the literature and suggests that the distinctive vascularity of the nose and the surrounding area may cause filler augmentation induced vascular complications in patients whose vascular circulation has already been compromised by a previous nose surgery.
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Dermal filler injection for face augmentation has gained popularity in the last decades which can be explained by the effectiveness and safety profile of the fillers. As the number of patients using fillers increases, the number of adverse events associated with injection may increase. The potential adverse events associated with fillers are injection site reaction, inappropriate placement, product sensitivity, infection, and necrosis. 1 Although most of the complications are transient, there are some irreversible adverse effects that can cause serious functional and aesthetic deficits.
Filler injection induced necrosis is a rare but important adverse event that is due to the direct injection of the filler into a vessel. 1 Blanching or pallor is a cardinal sign that suggests an arterial occlusion. On the other hand, red or bluish discoloration tends to suggest venous congestion. 2 Patients often develop severe pain and discoloration in the distribution of the occluded vessels. 3 Surgical rhinoplasty remains one of the most common procedures performed by plastic surgeons worldwide, with a huge popularity in Asia. 4 Unpredictable repositioning of blood vessels and a more tenuous blood supply in the operated nose may increase the risk of ischemia, necrosis, and vascular embolism following the filler injection. 4 We present seven consecutive patients with vascular compromise developing after filler injection, with all, noncoincidently, happened to have a history of rhinoplasty.
METHODS
This was a single-center study where data were collected retrospectively using our medical records from March 20, 2015 , to June 20, 2017 , to identify all patients who were treated at our center for vascular complications associated with facial hyaluronic acid filler injections. The study was conducted in accordance with Good Clinical Practices that have their origins in the Declaration of Helsinki. All patients were required to provide written informed consent, which included a photography release form.
In each case, we carefully reviewed the subject's demographic data (gender and age), habitual status, past medical and surgical history, the symptoms and clinical presentation at the first visit, the time interval between the injection and the onset of symptoms, injected filler material and brand, injection sites, the introduced treatment, and photographs.
RESULTS
Our retrospective review of the medical records over a twoyear period identified a total of 7 patients, each developing skin necrosis following injection of 1 to 2 cc of the hyaluronic acid filler. All patients were Asian with a mean age of 33 years (range, 25-52 years), all of whom were female. Both habitual history and past medical history of the patients were negative, but they all reported a cosmetic rhinoplasty more than 3 years ago.
All enrolled patients had received prior aesthetic treatment with hyaluronic acid filler between 1 to 17 days before their visits (mean, 6 days). The time interval between the injection and the onset of symptoms varied between 20 minutes and 3 days. The filler was injected for augmentation of either lips or nasolabial folds, and one patient reported a posterior nasal augmentation filler injection. Signs and symptoms that suggested a vascular complication were severe pain, tenderness, firm swelling, cyanotic discoloration, pustule formation, and necrosis. Administration of 100 to 300 units of hyaluronidase enzyme reversed the effects of hyaluronic acid filler in almost all the patients (Figures 1-6 and Supplemental Figure 1 ).
DISCUSSION
The use of dermal fillers has been growing rapidly over the past several years because of their safe, effective, and reproducible aesthetic results. Soft tissue fillers are widely injected in order to correct the rhytides, folds, and augmentation of deficits caused by aging and diseases. Recently filler rhinoplasty has joined the previous list. The ease of administration, the product's durability, and also the full reversibility of the treatment with hyaluronic acid fillers have made it the mainstay treatment for augmentation of the face. 2 The popularity of the dermal fillers over recent years is partially due to their impressive safety profiles. 1 However, different complication and adverse consequences can also occur with cosmetic procedures involving the injection of various agents. 5 The true incidence of these unwanted events has not been established, which could be because of the lack of a universal reporting system and underreporting by clinicians. 2 But it seems that as the number of procedures is increasing and larger volumes of fillers are in new treatment paradigms, the number of these complications is rising. 6 The filler induced adverse events can be classified as technical errors in terms of the volume, depth, and allocation of the injected filler, as well as the inflammatory complications which could be either infectious or immune mediated. 7 One of the most serious but statistically rare complications of dermal filler injection is skin necrosis. 8 Multiple mechanisms including vascular compression, vessel damage, and intraarterial filler emboli have been proposed to explain this complication. Chang et al introduced a mouse model, imaged with optical microangiography and laser speckle contrast imaging technologies, to elucidate the mechanism of filler-induced tissue ischemia. Their results demonstrated that intraarterial hyaluronic acid (HA) filler injection is the most likely etiology for filler-induced tissue necrosis that is observed clinically. 9 Further evaluation by 3-dimensional computed tomographic angiography and histopathological examination performed by Inoue et al, Kang et al, and Maruyama et al confirmed that the pathology of filler related ischemia is due to arterial embolism of filler that typically occurs immediately at the time of filler treatment. [10] [11] [12] Signs and symptoms that suggest the obstruction of the arterial blood supply include pain, pallor or blanching A B Figure 2 . (A) This patient was a 52-year-old woman who presented to our dermatology clinic with an erythematous pustule plaque that was tender on palpation. She mentioned that cosmetic rhinoplasty has been performed for her 28 years ago. She also reported HA filler injection (unknown brand) for augmentation of her nasolabial folds 8 days ago. She experienced severe pain 3 days after the injection and pustule formation in the following days. Oral Acyclovir had been provided by her physician, but the pain was continued and some minor areas of skin sloughing appeared afterward. (B) On arrival, we administered 300 units of Hyaluronidase along with triamcinolone injection. 3 days after the event, almost the entire skin defect was healed with minimal residual lesions.
phase, livedo phase, slow capillary refill, blue or gray-blue phase, demarcation phase, and finally repair and remodeling phase. 13 Typical clinical findings of vascular complication progression would be blanching, livedo pattern, blue-black discoloration, blister/bullae formation, skin breakdown, ulceration, demarcation, and slough. 13 Sometimes these signs and symptoms are confusing, resembling herpetic outbreaks. 6 Glabella and nasolabial folds have been reported as high risk and common areas for vascular occlusion and the resulted tissue necrosis. There are also fewer reports of tissue necrosis involving lip and nose following dermal filler injections. 2 The ala of the nose is particularly vulnerable to vascular complication and the following necrosis. 3 In nose augmentation, discoloration and necrosis is found on the nose, nasolabial fold, glabella, and forehead. 3 Treatment of the vascular complications, which begin with the diagnosis of the event, should continue with the administration of a significant amount of a hyaluronidase enzyme in the area of necrosis, applying a warm compress, massaging topical nitroglycerin (NTG) paste into the area, and introducing an oral aspirin regimen. 13, 14 Hyaluronidase is a soluble protein enzyme that degrades HA and is used to increase drug diffusion and reverse the effects of HA fillers. The immediate treatment with high doses of a hyaluronidase (at least 200 U) has been recommended in all cases of impending necrosis. 14 Recently, the successful treatment of a vascular compromise has been redefined as complete resolution of ischemia with no epidermal scabs, scarring, or any secondary changes whatsoever. The new approach which is called the high dose pulsed hyaluronidase (HDPH) protocol, uses the lip, nose, and forehead as dose multipliers, with the standard dose of about 500 IU per area. For a single region, starting with a dose of about 500 IU every hour or so, for two areas, A 33-year-old woman, who had received 2 ccs of HA filler injection (Teosyal®; Teoxane, Switzerland) for augmentation of her nasolabial folds, was referred to our dermatology clinic. She had experienced severe pain and swelling on the left side of her nose 3 days after the procedure, and pustules were formed in the following days. She mentioned that cosmetic rhinoplasty has been performed for her 4 years ago. Under the impression of herpes simplex infection, oral acyclovir had been prescribed. However, the skin lesion did not improve and worsened to necrosis. (Follow-up photos are not available.) 1000 IU, and 1500 IU for three areas, and retreating every 60 to 90 minutes until normal skin color returns have been recommended. 15 Surgical rhinoplasty remains one of the most common procedures performed by plastic surgeons worldwide, with a huge popularity in Asia. 4 Filler rhinoplasty is the use of fillers to correct cosmetic defects instead of surgery or in some cases to correct postsurgical defects following nose operation. 4 The blood supply to the external nose comes from the external and internal carotid arteries which are clinically relevant for filler injection in that area. 16 During an open rhinoplasty, the columellar arteries, which are branches of the facial or superior labial artery and provide blood flow to the nasal tip region, are divided by the transcolumellar incision. Furthermore, the lateral nasal arteries that follow the cephalic margin of the lateral crura and lateral collateral vessels may be transected during the surgery, leading to a decreased blood supply to the nasal skin. 17 Therefore, rhinoplasty may have altered the native vasculature of the nose 18 and some protective anastomoses within carotid circulation will likely have been compromised by the surgery. 4 There are numerous reports of facial necrosis following filler injection into the lips, nose and nasolabial fold. 16 As each report has studied just a small number of patients, there is insufficient information on contributing factors of filler-induced necrosis. We believe that the larger number of patients in our study and the evaluation of the potential factors contributing to the filler injection induced complications are the two main contributions of this article. We retrospectively reviewed our medical records over a two-year period, identifying a total of seven patients, each developing skin necrosis following injection of the hyaluronic acid filler. As all enrolled patients reported a cosmetic rhinoplasty a few years prior to their visit to the clinic, we suggested that it might not be a coincidental finding. It has been previously suggested that distinctive vascularity of the nose and the surrounding area may cause filler augmentation induced vascular complications in patients whose vascular circulation has already been compromised by a previous nose surgery. 4, [18] [19] [20] Our findings confirm the conjecture previously made in the literature and highlights the importance of the patient's history of previous cosmetic procedures including rhinoplasty in the emergence of vascular complications. In these cases, it is more critical to consider additional caution and to assess adequate tissue perfusion during injection. It may also be necessary to perform conservative staged injection allowing for a smaller volume of fillers to be injected to the area. 20 However, our study, as a preliminary report, faces some limitations mainly its small sample size and lack of comparison of vascular event following filler injection with those with no history of rhinoplasty. In addition to this, since the photos had been taken using a mobile phone while the patients were referred to our clinic for treatment, some of the images are not of high quality. It is hoped that our findings and recommendations are helpful in elucidating the possible role of previous rhinoplasty as a risk factor for skin necrosis following filler injection and encouraging further clinical investigation with larger sample size to compare the incidence or prevalence of vascular complications between patients with and without history of rhinoplasty.
CONCLUSIONS
This article emphasizes that clinicians who perform filler injection should be aware of the full history of previous cosmetic procedures of the patient and take necessary precautions to prevent the unpredicted vascular complications. An understanding of the facial vascular anatomy especially in postrhinoplasty patients helps the clinicians to better plan a filler injection.
